{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:53:47Z","timestamp":1781603627747,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Genet Genomics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00438-026-02426-y","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:18:50Z","timestamp":1781601530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["miR-133b induces antitumor immunity in cervical cancer through modulating CMTM6\/PD-L1 axis"],"prefix":"10.1007","volume":"301","author":[{"given":"Wei-Ming","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Ji","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"5","key":"2426_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","volume":"66","author":"AV Balar","year":"2017","unstructured":"Balar AV, Weber JS (2017) )PD-1 and PD-L1 antibodies in\u2002cancer: current status and future directions. Cancer Immunol Immunother 66(5):551\u2013564. https:\/\/doi.org\/10.1007\/s00262-017-1954-6","journal-title":"Cancer Immunol Immunother"},{"issue":"7670","key":"2426_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature23643","volume":"549","author":"ML Burr","year":"2017","unstructured":"Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA et al (2017) CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549(7670):101\u2013105. https:\/\/doi.org\/10.1038\/nature23643","journal-title":"Nature"},{"issue":"3","key":"2426_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC (2019) Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell 76(3):359\u2013370. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.030","journal-title":"Mol Cell"},{"issue":"17","key":"2426_CR4","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1056\/NEJMp058190","volume":"353","author":"CZ Chen","year":"2005","unstructured":"Chen CZ (2005) MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353(17):1768\u20131771. https:\/\/doi.org\/10.1056\/NEJMp058190","journal-title":"N Engl J Med"},{"key":"2426_CR5","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/ncomms6241","volume":"5","author":"L Chen","year":"2014","unstructured":"Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA et al (2014) Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5:5241. https:\/\/doi.org\/10.1038\/ncomms6241","journal-title":"Nat Commun"},{"key":"2426_CR6","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.2147\/CMAR.S237285","volume":"12","author":"X Chen","year":"2020","unstructured":"Chen X, Zhang Z, Ma Y, Su H, Xie P, Ran J (2020) LINC02381 Promoted Cell Viability and Migration via Targeting miR-133b in Cervical Cancer Cells. Cancer Manag Res 12:3971\u20133979. https:\/\/doi.org\/10.2147\/CMAR.S237285","journal-title":"Cancer Manag Res"},{"issue":"4","key":"2426_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41419-021-03690-z","volume":"12","author":"J Cheng","year":"2021","unstructured":"Cheng J, Ma H, Yan M, Xing W (2021) THAP9-AS1\/miR-133b\/SOX4 positive feedback loop facilitates the progression of esophageal squamous cell carcinoma. Cell Death Dis 12(4):401. https:\/\/doi.org\/10.1038\/s41419-021-03690-z","journal-title":"Cell Death Dis"},{"issue":"17","key":"2426_CR8","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","volume":"37","author":"HC Chung","year":"2019","unstructured":"Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R et al (2019) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 37(17):1470\u20131478. https:\/\/doi.org\/10.1200\/JCO.18.01265","journal-title":"J Clin Oncol"},{"issue":"20","key":"2426_CR9","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R et al (2021) Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med 385(20):1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa2112435","journal-title":"N Engl J Med"},{"issue":"39","key":"2426_CR10","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1038\/s41388-018-0347-4","volume":"37","author":"P Dong","year":"2018","unstructured":"Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S et al (2018) Control of PD-L1 expression by miR-140\/142\/340\/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer. Oncogene 37(39):5257\u20135268. https:\/\/doi.org\/10.1038\/s41388-018-0347-4","journal-title":"Oncogene"},{"key":"2426_CR11","doi-asserted-by":"publisher","unstructured":"Eichm\u00fcller SB, Osen W, Mandelboim O, Seliger B (2017) Immune modulatory microRNAs involved in tumor attack and tumor immune escape. J Natl Cancer Inst 109(10). https:\/\/doi.org\/10.1093\/jnci\/djx034","DOI":"10.1093\/jnci\/djx034"},{"key":"2426_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2017.08.006","volume":"407","author":"M Feng","year":"2017","unstructured":"Feng M, Xiong G, Cao Z, Yang G, Zheng S, Song X et al (2017) PD-1\/PD-L1 and immunotherapy for pancreatic cancer. Cancer Lett 407:57\u201365. https:\/\/doi.org\/10.1016\/j.canlet.2017.08.006","journal-title":"Cancer Lett"},{"key":"2426_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ebiom.2019.02.034","volume":"41","author":"L Gao","year":"2019","unstructured":"Gao L, Guo Q, Li X, Yang X, Ni H, Wang T et al (2019) MiR-873\/PD-L1 axis regulates the stemness of breast cancer cells. EBioMedicine 41:395\u2013407. https:\/\/doi.org\/10.1016\/j.ebiom.2019.02.034","journal-title":"EBioMedicine"},{"key":"2426_CR14","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.2147\/OTT.S249667","volume":"13","author":"Y Guo","year":"2020","unstructured":"Guo Y, Lu G, Mao H, Zhou S, Tong X, Wu J et al (2020) miR-133b Suppresses Invasion and Migration of Gastric Cancer Cells via the COL1A1\/TGF-\u03b2 Axis. Onco Targets Ther 13:7985\u20137995. https:\/\/doi.org\/10.2147\/OTT.S249667","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2426_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4110\/in.2011.11.1.11","volume":"11","author":"TY Ha","year":"2011","unstructured":"Ha TY (2011) The role of MicroRNAs in regulatory T cells and in the immune response. Immune Netw 11(1):11\u201341","journal-title":"Immune Netw"},{"issue":"7","key":"2426_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.ccell.2023.05.014","volume":"41","author":"P Ho","year":"2023","unstructured":"Ho P, Melms JC, Rogava M, Frangieh CJ, Po\u017aniak J, Shah SB et al (2023) The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. Cancer Cell 41(7):1207\u20131221e12. https:\/\/doi.org\/10.1016\/j.ccell.2023.05.014","journal-title":"Cancer Cell"},{"issue":"2","key":"2426_CR17","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1080\/21655979.2022.2027063","volume":"13","author":"L Jiang","year":"2022","unstructured":"Jiang L, Wang X (2022) The miR-133b\/brefeldin A-inhibited guanine nucleotide-exchange protein 1 (ARFGEF1) axis represses proliferation, invasion, and migration in cervical cancer cells. Bioengineered 13(2):3323\u20133332. https:\/\/doi.org\/10.1080\/21655979.2022.2027063","journal-title":"Bioengineered"},{"key":"2426_CR18","doi-asserted-by":"publisher","first-page":"10275","DOI":"10.2147\/OTT.S226465","volume":"12","author":"W Jiang","year":"2019","unstructured":"Jiang W, Li T, Wang J, Jiao R, Shi X, Huang X, Ji G (2019) miR-140-3p Suppresses Cell Growth And Induces Apoptosis In Colorectal Cancer By Targeting PD-L1. Onco Targets Ther 12:10275\u201310285. https:\/\/doi.org\/10.2147\/OTT.S226465","journal-title":"Onco Targets Ther"},{"key":"2426_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.biopha.2018.02.022","volume":"101","author":"LW Jin","year":"2018","unstructured":"Jin LW, Ye HY, Xu XY, Zheng Y, Chen Y (2018) MiR-133a\/133b inhibits Treg differentiation in IgA nephropathy through targeting FOXP3. Biomed Pharmacother 101:195\u2013200. https:\/\/doi.org\/10.1016\/j.biopha.2018.02.022","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"2426_CR20","doi-asserted-by":"publisher","first-page":"e1629261","DOI":"10.1080\/2162402X.2019.1629261","volume":"8","author":"YW Koh","year":"2019","unstructured":"Koh YW, Han JH, Haam S, Jung J, Lee HW (2019) Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients. Oncoimmunology 8(10):e1629261. https:\/\/doi.org\/10.1080\/2162402X.2019.1629261","journal-title":"Oncoimmunology"},{"key":"2426_CR21","doi-asserted-by":"publisher","first-page":"153473541989002","DOI":"10.1177\/1534735419890020","volume":"8","author":"JX Li","year":"2019","unstructured":"Li JX, Huang JM, Jiang ZB, Li RZ, Sun A, Lai-Han Leung E, Yan PY (2019) Current Clinical Progress of PD-1\/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer. Integr Cancer Ther 8:1534735419890020. https:\/\/doi.org\/10.1177\/1534735419890020","journal-title":"Integr Cancer Ther"},{"issue":"1","key":"2426_CR22","doi-asserted-by":"publisher","first-page":"1864909","DOI":"10.1080\/2162402X.2020.1864909","volume":"10","author":"S Martinez-Morilla","year":"2020","unstructured":"Martinez-Morilla S, Zugazagoitia J, Wong PF, Kluger HM, Rimm DL (2020) Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. Oncoimmunology 10(1):1864909. https:\/\/doi.org\/10.1080\/2162402X.2020.1864909","journal-title":"Oncoimmunology"},{"issue":"7670","key":"2426_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature23669","volume":"549","author":"R Mezzadra","year":"2017","unstructured":"Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W et al (2017) Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549(7670):106\u2013110. https:\/\/doi.org\/10.1038\/nature23669","journal-title":"Nature"},{"issue":"10","key":"2426_CR24","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.ccell.2023.08.008","volume":"9","author":"B Miao","year":"2023","unstructured":"Miao B, Hu Z, Mezzadra R, Hoeijmakers L, Fauster A, Du S et al (2023) CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. Cancer Cell 9(10):1817\u20131828. https:\/\/doi.org\/10.1016\/j.ccell.2023.08.008","journal-title":"Cancer Cell"},{"key":"2426_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"issue":"36","key":"2426_CR26","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1038\/onc.2011.561","volume":"31","author":"W Qin","year":"2012","unstructured":"Qin W, Dong P, Ma C, Mitchelson K, Deng T, Zhang L et al (2012) MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways. Oncogene 31(36):4067\u20134075. https:\/\/doi.org\/10.1038\/onc.2011.561","journal-title":"Oncogene"},{"key":"2426_CR27","doi-asserted-by":"publisher","unstructured":"Rotte A, Jin JY, Lemaire V (2018) Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol 29(1):71\u201383. https:\/\/doi.org\/10.1093\/annonc\/mdx686.29:71\u201383","DOI":"10.1093\/annonc\/mdx686.29"},{"issue":"38","key":"2426_CR28","doi-asserted-by":"publisher","first-page":"e17257","DOI":"10.1097\/MD.0000000000017257","volume":"98","author":"M Sharma","year":"2019","unstructured":"Sharma M, Yang Z, Miyamoto H (2019) Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer. Med (Baltim) 98(38):e17257. https:\/\/doi.org\/10.1097\/MD.0000000000017257","journal-title":"Med (Baltim)"},{"issue":"3","key":"2426_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2426_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/intimm\/dxaa018","volume":"32","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto Y, Kakizaki M, Shimizu T, Carreras J, Chiba T, Chamoto K et al (2020) PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir. Int Immunol 32(8):519\u2013531. https:\/\/doi.org\/10.1093\/intimm\/dxaa018","journal-title":"Int Immunol"},{"issue":"1","key":"2426_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12943-022-01608-7","volume":"21","author":"B Yao","year":"2022","unstructured":"Yao B, Zhang Q, Yang Z, An F, Nie H, Wang H et al (2022) CircEZH2\/miR-133b\/IGF2BP2 aggravates colorectal cancer progression via enhancing the stability of m6A-modified CREB1 mRNA. Mol Cancer 21(1):140. https:\/\/doi.org\/10.1186\/s12943-022-01608-7","journal-title":"Mol Cancer"},{"issue":"19","key":"2426_CR33","doi-asserted-by":"publisher","first-page":"31347","DOI":"10.18632\/oncotarget.15532","volume":"8","author":"M Zhang","year":"2017","unstructured":"Zhang M, Sun H, Zhao S, Wang Y, Pu H, Wang Y, Zhang Q (2017) Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget 8(19):31347\u201331354. https:\/\/doi.org\/10.18632\/oncotarget.15532","journal-title":"Oncotarget"},{"issue":"7686","key":"2426_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT et al (2018) Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553(7686):91\u201395. https:\/\/doi.org\/10.1038\/nature25015","journal-title":"Nature"},{"issue":"1","key":"2426_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/cimb48010064","volume":"48","author":"Z Zhou","year":"2026","unstructured":"Zhou Z, Li J, Zhao X, Xu H, Xiao Y, Wang H et al (2026) Gramine Suppresses Cervical Cancer by Targeting CDK2: Integrated Omics-Pharmacology and In Vitro Evidence. Curr Issues Mol Biol 48(1):64. https:\/\/doi.org\/10.3390\/cimb48010064","journal-title":"Curr Issues Mol Biol"},{"issue":"12","key":"2426_CR35","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.jtho.2019.09.014","volume":"14","author":"J Zugazagoitia","year":"2019","unstructured":"Zugazagoitia J, Liu Y, Toki M, McGuire J, Ahmed FS, Henick BS et al (2019) Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. J Thorac Oncol 14(12):2084\u20132096. https:\/\/doi.org\/10.1016\/j.jtho.2019.09.014","journal-title":"J Thorac Oncol"}],"container-title":["Molecular Genetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00438-026-02426-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00438-026-02426-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00438-026-02426-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:18:51Z","timestamp":1781601531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00438-026-02426-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2426"],"URL":"https:\/\/doi.org\/10.1007\/s00438-026-02426-y","relation":{},"ISSN":["1617-4615","1617-4623"],"issn-type":[{"value":"1617-4615","type":"print"},{"value":"1617-4623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The use of human samples gained the approval of the Ethics Committee of Wuhan Sixth Hospital (2022Q0711). All the recruited subjects signed the written informed consent. All the sample handling and data processing steps were following the Declaration of Helsinki. Animal protocols were in compliance with the guidelines of animal care and welfare and were approved by the Experimental Animal Ethics Committee of Wuhan Sixth Hospital (WSHA-20220586-03).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"140"}}